

Did you miss Neola Medical's Q2 report presentation?

Catch up on Neola Medical's Q2 highlights, including the successful enrollment of the first preterm born baby in the clinical pilot study in Sweden and advancing preparations for the pivotal U.S. clinical study.

CEO Hanna Sjöström shares insights into these key milestones, recent patent progress, and our strengthened U.S. presence as we continue to advance toward FDA market authorization. CFO David Folkesson presents the financial results for Q2 2025.

Watch the full report presentation and stay for the Q&A session. Tune in here:

[Finwire TV: Neola Medical Q2 presentation 2025](#)

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung complications in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on a spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola Medical builds on Sweden's longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Image Attachments

[Q2 Presentation 2025](#)

Attachments

[Did you miss Neola Medical's Q2 report presentation?](#)